Alkem Labs partners with hospitals for its 'Reliever Free India' initiative on World Asthma Day

Alkem Labs collaborates with 100 hospitals in tier-1 & tier-2 cities under its 'Reliever Free India' initiative on World Asthma Day

Overview

In recognition of World Asthma Day 2024, Alkem Laboratories (Alkem) announced 600 to 700 camps across India, collaborating with nearly 100 hospitals in tier-1 and tier-2 cities under its ""Reliever Free India"" initiative. This nationwide initiative was launched in 2023 with an aim to revolutionize asthma management by advocating for a shift in focus from reliance on reliever medications to the importance of controller medications. Reliever medications provide quick relief during asthma symptoms by opening up the airways. Controller medications are taken regularly to prevent asthma symptoms and reduce inflammation in the airways. After a successful first year, Alkem is intensifying the campaign in its second year. 

Impact of Asthma

• Asthma affects a staggering 262 million people globally, causing recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.
• Despite advancements in medical treatment, asthma remains a significant challenge for patients and healthcare providers alike. 
• Alkem recognizes the critical role that education plays in empowering individuals to effectively manage their asthma and lead fulfilling lives. 

Words from Alkem Laboratories

Alkem Laboratories Spokesperson said, “We've engaged with over 500 camps since the start of our campaign. This year, we're expanding our commitment by organizing at least 600 camps and clinics to raise awareness about asthma and its management. Our goal is to empower patients with the knowledge they need to take control of their health. Through the 'Reliever Free India' campaign, we're promoting a proactive approach to asthma management, aiming to improve outcomes and enhance quality of life for individuals with this condition.”
 
Reliever Free India

• The ""Reliever Free India"" campaign emphasizes the importance of using controller medications for optimal asthma management. While reliever medications offer immediate relief during asthma attacks, they do not address the underlying inflammation that contributes to the condition's chronic nature. 
• Over-reliance on relievers can lead to poor long-term outcomes and increased risk of exacerbations. 
• Through this campaign, Alkem Laboratories seeks to educate patients, healthcare professionals, and the general public about the benefits of controller medications in preventing asthma symptoms and reducing the need for rescue medication. 

World Asthma Day

This World Asthma Day, Alkem Laboratories invites everyone to join hands in raising awareness, fostering understanding, and empowering individuals with asthma to live their lives to the fullest. Together, we can create a world where asthma is not a barrier to a healthy and fulfilling life.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!